Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Invites Public To View And Listen To Webcast Of April 28 Conference Call With Analysts

Business Wire March 24, 2015

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Business Wire March 23, 2015

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

Business Wire March 20, 2015

Results of Pfizer's Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine

Business Wire March 18, 2015

Help Protect Texas' Babies: Make sure your children are fully vaccinated

PR Newswire March 18, 2015

Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia

Business Wire March 12, 2015

A.M. Best Affirms Ratings of Blue Whale Re Ltd.

Business Wire March 11, 2015

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Business Wire March 3, 2015

CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk

Business Wire February 26, 2015

Nodality Inc. Presents Data from Immuno-Oncology Program Applying Company's Novel Single Cell Network Profiling (SCNP) Platform

Business Wire February 25, 2015

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire February 24, 2015

Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis (Tdap) Vaccines In Adolescents

Business Wire February 24, 2015

FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM)

Business Wire February 20, 2015

Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride)

Business Wire February 13, 2015

Pfizer Commences $5 Billion Accelerated Share Repurchase

Business Wire February 9, 2015

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Investor Conference

Business Wire February 9, 2015

HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of the Hospira, Inc. Board of Directors in Connection to the Proposed Sale of the Company to Pfizer, Inc. - HSP

PR Newswire February 6, 2015

HOSPIRA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hospira, Inc.

PR Newswire February 5, 2015

Block & Leviton LLP Investigates Hospira, Inc. for Possible Breaches of Fiduciary Duty in Connection with Their Proposed Acquisition by Pfizer Inc.

PR Newswire February 5, 2015

HOSPIRA, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

PR Newswire February 5, 2015